Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder

Kei Nagao,1,2 Taro Kishi,1 Masatsugu Moriwaki,1 Kiyoshi Fujita,3,4 Shigeki Hirano,5 Yoshio Yamanouchi,1 Toshihiko Funahashi,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, The Jindai Hospital, Toyota, Aichi, Jap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nagao K, Kishi T, Moriwaki M, Fujita K, Hirano S, Yamanouchi Y, Funahashi T, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/de2e1ba97dc04e0981a8943b9fdfdbc4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de2e1ba97dc04e0981a8943b9fdfdbc4
record_format	dspace
spelling	oai:doaj.org-article:de2e1ba97dc04e0981a8943b9fdfdbc42021-12-02T05:52:26ZComparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder1176-63281178-2021https://doaj.org/article/de2e1ba97dc04e0981a8943b9fdfdbc42013-06-01T00:00:00Zhttp://www.dovepress.com/comparative-clinical-profile-of-mirtazapine-and-duloxetine-in-practica-a13238https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Kei Nagao,1,2 Taro Kishi,1 Masatsugu Moriwaki,1 Kiyoshi Fujita,3,4 Shigeki Hirano,5 Yoshio Yamanouchi,1 Toshihiko Funahashi,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, The Jindai Hospital, Toyota, Aichi, Japan; 3Department of Psychiatry, The Okehazama Hospital, Toyoake, Aichi, Japan; 4The Neuroscience Research Center, Toyoake, Aichi, Japan; 5Department of Psychiatry, The Toyota Memorial Hospital, Toyota, Aichi, Japan Abstract: No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n = 34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery–Åsberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P < 0.0001–0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD. Keywords: mirtazapine, duloxetine, major depressive disorderNagao KKishi TMoriwaki MFujita KHirano SYamanouchi YFunahashi TIwata NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 781-786 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Nagao K Kishi T Moriwaki M Fujita K Hirano S Yamanouchi Y Funahashi T Iwata N Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
description	Kei Nagao,1,2 Taro Kishi,1 Masatsugu Moriwaki,1 Kiyoshi Fujita,3,4 Shigeki Hirano,5 Yoshio Yamanouchi,1 Toshihiko Funahashi,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, The Jindai Hospital, Toyota, Aichi, Japan; 3Department of Psychiatry, The Okehazama Hospital, Toyoake, Aichi, Japan; 4The Neuroscience Research Center, Toyoake, Aichi, Japan; 5Department of Psychiatry, The Toyota Memorial Hospital, Toyota, Aichi, Japan Abstract: No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n = 34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery–Åsberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P < 0.0001–0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD. Keywords: mirtazapine, duloxetine, major depressive disorder
format	article
author	Nagao K Kishi T Moriwaki M Fujita K Hirano S Yamanouchi Y Funahashi T Iwata N
author_facet	Nagao K Kishi T Moriwaki M Fujita K Hirano S Yamanouchi Y Funahashi T Iwata N
author_sort	Nagao K
title	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
title_short	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
title_full	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
title_fullStr	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
title_full_unstemmed	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
title_sort	comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in japan: a 4-week open-label, parallel-group study of major depressive disorder
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/de2e1ba97dc04e0981a8943b9fdfdbc4
work_keys_str_mv	AT nagaok comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT kishit comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT moriwakim comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT fujitak comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT hiranos comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT yamanouchiy comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT funahashit comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder AT iwatan comparativeclinicalprofileofmirtazapineandduloxetineinpracticalclinicalsettingsinjapana4weekopenlabelparallelgroupstudyofmajordepressivedisorder
_version_	1718400202442801152

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder

Ejemplares similares